ESSA Pharma announced that it has entered into a definitive agreement with Realm Therapeutics setting forth the terms of an acquisition whereby ESSA will acquire all of the issued and outstanding shares of Realm in an all-stock transaction.
Takeda Pharmaceutical and Frazier Healthcare Partners have announced a collaboration to launch Phathom Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders.
A new biotechnology holding company in the form of ElevateBio has been launched in Cambridge, Massachusetts with an objective to develop a portfolio of cell and gene therapy companies.
Zymeworks has entered into a licensing agreement that grants Iconic Therapeutics non-exclusive rights to Zymeworks’ proprietary ZymeLink antibody-drug conjugate (ADC) platform for the development of its ICON-2 Tissue Factor ADC for cancer.
Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, announced today the closure of an asset purchase and license agreement with ImmunGene, a privately held biotechnology company.
Magenta Therapeutics, a clinical-stage biotechnology company, announced that the company presented Phase 2 clinical data on its cell therapy, MGTA-456, at the annual meeting of the American Academy of Neurology in Philadelphia, Pennsylvania.
Pfizer announced that it has entered into a definitive agreement to acquire all the shares of Therachon Holding AG, a privately-held clinical-stage biotechnology company focused on rare diseases, with assets in development for the treatment of achondroplasia and short bowel syndrome (SBS).
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of economic rights to SB206 from Novan, Inc. SB206 is a Phase 3 topical antiviral gel for the treatment of skin infections, including molluscum contagiosum.
Danish pharma company H. Lundbeck has agreed to acquire Abide Therapeutics, a US-based clinical-stage biopharma company, in a deal worth up to $400m.
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies against cancers and infectious diseases announces the signing of a collaborative research, option and exclusive license agreement with AstraZeneca to co-develop five armed oncolytic vaccinia virus candidates.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.